Perforated tissue matrix
US-2024408277-A1 · Dec 12, 2024 · US
Implants and biodegradable tissue markers
US2025161497A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025161497-A1 |
| Application number | US-202519029785-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 17, 2025 |
| Priority date | Dec 15, 2009 |
| Publication date | May 22, 2025 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.
First claim
Opening claim text (preview).
1 - 15 . (canceled) 16 . A method for radiation therapy comprising introducing a hydrogel spacer at a site between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, the site being chosen to decrease radiation at the first tissue when the second tissue receives a dose of therapeutic radiation, wherein the hydrogel spacer comprises a collection of covalently-crosslinked, hydrolytically biodegradable hydrogel particles comprising a polysaccharide, and a linear polymer. 17 . The method of claim 16 , wherein the first tissue location is associated with the rectum and the second tissue location is associated with the prostate gland. 18 . The method of claim 16 , wherein the hydrogel spacer, as placed in the tissue, has a volume between 1 and 40 ml. 19 . The method of claim 16 , wherein the hydrogel particles are formed by a process comprising breaking up a hydrogel polymer matrix. 20 . The method of claim 16 , wherein the polysaccharide is hyaluronic acid. 21 . The method of claim 16 , wherein the linear polymer comprises a hydrophilic polymer having a molecular weight from about 500 to about 100,000 Da. 22 . The method of claim 16 , wherein the hydrogel spacer comprises from about 1% to about 50% w/w of the linear polymer. 23 . The method of claim 16 , wherein the linear polymer comprises polyethylene glycol. 24 . The method of claim 16 , wherein the hydrogel spacer is visible under ultrasound. 25 . The method of claim 24 , further comprising imaging the interface of the hydrogel spacer and the second tissue using ultrasound. 26 . The method of claim 25 , wherein the hydrogel spacer is echolucent under ultrasound imaging. 27 . The method of claim 16 , wherein the hydrogel spacer has a Hounsfield number of at least about 90 and wherein the hydrogel spacer comprises a radiopaque agent. 28 . The method of claim 27 , wherein the radiopaque agent is a covalently attached radiopaque iodine agent. 29 . The method of claim 16 , wherein the hydrogel spacer further comprises a therapeutic agent. 30 . A method for radiation therapy comprising introducing a hydrogel spacer at a site between a first tissue location and a second tissue location to increase a distance between the first tissue location and the second tissue location, the site being chosen to decrease radiation at the first tissue when the second tissue receives a dose of therapeutic radiation, wherein the hydrogel spacer comprises a collection of covalently-crosslinked hydrolytically biodegradable hydrogel particles comprising a polysaccharide, and a linear polymer, wherein the polysaccharide is hyaluronic acid and wherein the hydrogel spacer is visible under ultrasound. 31 . The method of claim 30 , wherein the first tissue location is associated with the rectum and the second tissue location is associated with the prostate gland. 32 . The method of claim 30 , wherein the hydrogel spacer is echolucent under ultrasound imaging. 33 . The method of claim 30 , wherein the hydrogel spacer, as placed in the tissue, has a volume between 1 and 40 ml. 34 . The method of claim 30 , wherein the hydrogel particles are formed by a process comprising breaking up a hydrogel polymer matrix. 35 . The method of claim 30 , wherein the linear polymer comprises a hydrophilic polymer having a molecular weight from about 500 to about 100,000 Da.
Assignees
Inventors
Classifications
Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer · CPC title
Materials at least partially X-ray or laser opaque · CPC title
Materials at least partially resorbable by the body · CPC title
Hydrogels or hydrocolloids · CPC title
Materials at least partially resorbable by the body · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2025161497A1 cover?
- Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.
- Who is the assignee on this patent?
- Incept Llc
- What technology area does this patent fall under?
- Primary CPC classification A61L27/50. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu May 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).